Therapeutic | Glenzocimab |
Target | GP6 |
Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGRDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Fab |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Acticor Biotech |
Conditions Approved | na |
Conditions Active | Stroke |
Conditions Discontinued | na |
Notes |